Zimbabwe Pharmaceutical Market Overview

The Zimbabwe Pharmaceutical Market Size Was Valued At USD 244 Million In 2022 And Is Projected To Reach USD 341.72 Million By 2030, Registering A CAGR Of 4.3% From 2023 To 2030.

Pharmaceutical products, also known as medicines or drugs, are specialized preparations used in both modern and traditional treatment. They are critical for illness prevention and treatment, as well as public health protection. The use of ineffective, low-quality, or toxic pharmaceuticals can result in therapeutic failure, disease exacerbation, drug resistance, and, in some cases, death. It also reduces trust in healthcare systems, healthcare practitioners, pharmaceutical makers, and distributors. Thus, to prevent the circulation of counterfeit products in the market, stringent regulations are required. According to the United Nations World Population Ageing Report 2019, Zimbabwe's population of individuals aged 65 and above was estimated to be 437,000 in 2019 and is expected to reach 1,297,000 by 2050. The geriatric population is prone to infectious and other age-related diseases. They are susceptible to chronic diseases such as cardiovascular disease, cancer, and gastrointestinal problems. Additionally, HIV, tuberculosis (TB), and malaria are the top three health threats faced by individuals. The increasing prevalence of these diseases has propelled the demand for new therapies. Furthermore, to capitalize on the growing pharma market, several global market players have entered Zimbabwe. The entry of global players coupled with the increasing cases of infectious diseases is anticipated to strengthen the growth of the Zimbabwe Pharmaceutical market over the forecasted period.

Market Dynamics and Factors for Zimbabwe Pharmaceutical Market:

Drivers:

Growing Prevalence of HIV And Other Viral Diseases

Zimbabwe has a widespread HIV epidemic, with 1.27 million people living with HIV (PLHIV), including 1.19 million adults and 69,972 children. In 2020, an estimated 1.27 million people were living with HIV, with 5.53 % of them being children aged 0-14. 60.6% of HIV-positive adults aged 15 and above were female. Annual all-cause deaths among PLHIV have decreased over the last decade, with approximately 28,201 all-cause deaths expected in 2020, down from 127,871 in 2003. Total new HIV infections in Zimbabwe have decreased from 98,668 in 2003 to 24,524 in 2020. ART coverage among all HIV-positive adults was 92% for adult men and 93% for adult women by the end of 2020. Children's coverage was slightly lower, at 66%.

According to the Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) 2020, overall HIV prevalence for adults aged 15-49 was 11.8% in 2020, down from 18.1% in the ZDHS in 2005. HIV prevalence varied geographically in the 2020 ZIMPHIA, with higher prevalence in Matabeleland North (14.9%), Bulawayo (14.0%), and Matabeleland South (17.6%) than in the other seven provinces, which were all below 14%. The highest estimated HIV prevalence was nearly 30% for both males (30.9%) and females (33.3%) but occurred at a slightly older age (50-54 years) in males than females (45-49 years). The gender disparity in HIV prevalence was most pronounced among young individuals, with females (6.4%) having three times the prevalence of males (2.8%) aged 20 to 24 years. Though there has been a steep decline in new cases, the demand for ART to treat infected individuals has increased. With support from the President’s Emergency Plan for AIDS Relief (PEPFAR) in the USA, ART coverage has increased nationally. This growth in ART coverage is anticipated to support the growth of the Zimbabwe pharmaceutical market over the analysis period.

Restraints:

Poverty and Declining Economy

Zimbabwe's weak economy will continue to constrain pharmaceutical and healthcare market growth as household incomes and government tax revenues remain low. In addition, Zimbabwe's annual consumer price inflation increased to 285% in August 2022, up from 256.9% the previous month. It was the highest reading since February 2021, amid general increases in all categories of goods and services, particularly food, due to failed harvests caused by droughts. Over the last seven months, the country has faced severe inflationary pressures, which have been attributed to exchange rate volatility and external factors such as the Russia - Ukraine war. This rise in consumer price inflation restricts most civilians from purchasing essential medicines. Despite the support from foreign investments, Zimbabwe's weak economic environment will continue to disincentivize investors from entering the market thereby, hampering the development of the Zimbabwe pharmaceutical market growth over the forecasted period.

Opportunities:

Government Initiatives to Support the Local Pharmaceutical Production

In terms of meeting drug and export requirements, the Zimbabwe Pharmaceutical Industry has proven to be strategic. The sector has thus been prioritized for resuscitation in the National Development Strategy 1 (2021-2025), Zimbabwe National Industrial Policy (2019 - 2023), and the Local Content Strategy to strengthen the local production of essential medicines. Zimbabwe's pharmaceutical industry is made up of nine pharmaceutical companies: CAPS Pharmaceuticals, Varichem Pharmaceuticals, Pharmanova, Datlabs, Plus Five Pharmaceuticals, ZimPharm Graniteside, and Gulf Drug, manufactures human medicines, while Ecomed manufactures veterinary products. These companies account only for 12% of the total medicines consumed as they mostly manufacture generic medicines.

Additionally, they are not compliant with standards set by the World Health Organization (Good Manufacturing Practices). The financial requirement for the implementation of the strategy is USD 45 million, out of which USD 43 million will be allocated to the costs for GMP upgrading and product development and US$ 2 million for support infrastructure. This support from the government will help the local companies to comply with GMP standards set by the WHO resulting in the production of anti-retroviral drugs that are mostly imported from countries. The introduction of the Pharmaceutical Manufacturing Strategy in Zimbabwe is anticipated to create lucrative opportunities for local market players over the forecasted period.

Segmentation Analysis of Zimbabwe Pharmaceutical Market

By Drug Type, the prescription drug segment is anticipated to dominate throughout the forecasted period. The prevalence of Malaria, HIV, Tuberculosis, and Human Papilloma Virus (HOV) are some of the major diseases that have contributed to the growth of prescription drugs in the country. According to WHO, it was estimated that 29,000 people were diagnosed with TB in 2020, and about 2,100 of these succumbed to the disease. Additionally, the country also reports a large number of malarial cases every year. Malaria is still one of Zimbabwe's top three causes of illness and death. Pregnant women and children under the age of five are among the most vulnerable, and more than half of the population lives in high-risk areas. Malaria cases increased by 58% from 242,951 in 2019 to 384,956 in 2020, according to the Ministry of Health and Child Care. This growth in cases represents a rise in the demand for prescription drugs. Drugs that are administered for the treatment of HIV and Malaria are prescribed and are not sold OTC thus, supporting the expansion of the segment in the projected period.

By Therapeutic Category, the antiviral segment is estimated to lead the growth of the Zimbabwe pharmaceutical market during the analysis period. Antivirals are medications that help fight off certain viruses that can cause disease. Antivirals are preventive as well as treatment drugs. The growing prevalence of HIV, malaria, and respiratory infections has raised the demand for antiviral drugs. The recent outbreak of COVID-19 further increased the demand for an antiviral drugs. According to WHO, 257,156 confirmed cases of COVID-19 were reported till September 2022. Though the number of confirmed cases has declined in recent months, however, the pandemic is not over yet. In addition, the prevalence of other viral diseases is anticipated to strengthen the growth of the segment throughout the projected period.

By Distribution Channel, the hospital pharmacy segment is expected to have the highest share of the market. The growth of this segment is mainly attributed to the increasing visit to primary healthcare settings such as hospitals. Hospital pharmacies have most of the medications in stock and provide them at reasonable rates. As these are government-funded pharmacies, the cost of overall treatment decreases as most of the medications are generic. With the declining economy in Zimbabwe, individuals are preferring hospital pharmacies over other options thereby, helping the development of the segment.

COVID-19 Impact on Zimbabwe Pharmaceutical Market

The COVID-19 outbreaks have had a substantial impact on Zimbabwe's pharmaceutical business since there has been an increase in demand for therapeutics in the treatment of COVID-19-infected individuals, which has led to a rise in large-scale pharmaceutical product manufacturing in the country. However, due to lockdown measures, the supply network between the rest of the world and the country was disrupted, and so local manufacturers played a vital role during the COVID-19 pandemic. According to the research article "Impact of COVID-19 on Supply Chains in Zimbabwe," published in the Journal of Public Health International 2020, the disruption of medical supplies such as pharmaceuticals during the pandemic has provided a great opportunity for Zimbabwe to be less dependent on foreign medical supplies, thereby increasing local therapeutic manufacturing. Moreover, throughout the pandemic, the Zimbabwean Ministry of Health and ChildCare (MOHCC) was active in initiatives to increase the country's ability to produce medical supplies through several organizations such as Varichem, CAPS, Natpharma, and Avail Pharmaceuticals. As a result, the above factors are projected to have a substantial impact on the market growth.

Top Key Players Covered In Zimbabwe Pharmaceutical Market

• Bayer AG
• CAPS Pharmaceuticals
• Pfizer Inc
• Plus Five Pharmaceuticals
• ZimPharm Graniteside
• Pharmanova
• Gulf Drug
• Datlabs
• GlaxoSmithKline PLC
• Icon Pharmaceuticals
• Varichem
• Seasons Pharmaceuticals
• Graniteside Chemicals (Pvt) Ltd, and Other Major Players

Key Industry Developments In Zimbabwe Pharmaceutical Market

• In February 2021, Pfizer and the IDA Foundation announced a collaboration to deliver equitable access to effective cancer therapies in nearly 70 developing countries across Latin America, Asia, Africa, and the Western Pacific area. Due to the supply agreement, millions more patients will be able to obtain new chemotherapy medications for a variety of cancers.
• In December 2021, ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, announced that Apretude, the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually acquired HIV-1, has been approved by the US Food and Drug Administration (FDA). This drug will be available to patients in Zimbabwe.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Drug Type
 3.2 By Therapeutic Category
 3.3 By Distribution Channel

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Zimbabwe Pharmaceutical Market by Drug Type
 5.1 Zimbabwe Pharmaceutical Market Overview Snapshot and Growth Engine
 5.2 Zimbabwe Pharmaceutical Market Overview
 5.3 Prescription Drugs
  5.3.1 Introduction and Market Overview
  5.3.2 Key Market Trends, Growth Factors and Opportunities
  5.3.3 Impact of Covid-19
  5.3.4 Historic and Forecasted Market Size (2016-2028F)
  5.3.5 Key Market Trends, Growth Factors and Opportunities
  5.3.6 Prescription Drugs: Geographic Segmentation
 5.4 OTC Drugs
  5.4.1 Introduction and Market Overview
  5.4.2 Key Market Trends, Growth Factors and Opportunities
  5.4.3 Impact of Covid-19
  5.4.4 Historic and Forecasted Market Size (2016-2028F)
  5.4.5 Key Market Trends, Growth Factors and Opportunities
  5.4.6 OTC Drugs: Geographic Segmentation

Chapter 6: Zimbabwe Pharmaceutical Market by Therapeutic Category
 6.1 Zimbabwe Pharmaceutical Market Overview Snapshot and Growth Engine
 6.2 Zimbabwe Pharmaceutical Market Overview
 6.3 Cardiovascular Disorders
  6.3.1 Introduction and Market Overview
  6.3.2 Key Market Trends, Growth Factors and Opportunities
  6.3.3 Impact of Covid-19
  6.3.4 Historic and Forecasted Market Size (2016-2028F)
  6.3.5 Key Market Trends, Growth Factors and Opportunities
  6.3.6 Cardiovascular Disorders: Geographic Segmentation
 6.4 Anti-viral
  6.4.1 Introduction and Market Overview
  6.4.2 Key Market Trends, Growth Factors and Opportunities
  6.4.3 Impact of Covid-19
  6.4.4 Historic and Forecasted Market Size (2016-2028F)
  6.4.5 Key Market Trends, Growth Factors and Opportunities
  6.4.6 Anti-viral: Geographic Segmentation
 6.5 Respiratory Diseases
  6.5.1 Introduction and Market Overview
  6.5.2 Key Market Trends, Growth Factors and Opportunities
  6.5.3 Impact of Covid-19
  6.5.4 Historic and Forecasted Market Size (2016-2028F)
  6.5.5 Key Market Trends, Growth Factors and Opportunities
  6.5.6 Respiratory Diseases: Geographic Segmentation
 6.6 Others
  6.6.1 Introduction and Market Overview
  6.6.2 Key Market Trends, Growth Factors and Opportunities
  6.6.3 Impact of Covid-19
  6.6.4 Historic and Forecasted Market Size (2016-2028F)
  6.6.5 Key Market Trends, Growth Factors and Opportunities
  6.6.6 Others: Geographic Segmentation

Chapter 7: Zimbabwe Pharmaceutical Market by Distribution Channel
 7.1 Zimbabwe Pharmaceutical Market Overview Snapshot and Growth Engine
 7.2 Zimbabwe Pharmaceutical Market Overview
 7.3 Hospital Pharmacies
  7.3.1 Introduction and Market Overview
  7.3.2 Key Market Trends, Growth Factors and Opportunities
  7.3.3 Impact of Covid-19
  7.3.4 Historic and Forecasted Market Size (2016-2028F)
  7.3.5 Key Market Trends, Growth Factors and Opportunities
  7.3.6 Hospital Pharmacies: Geographic Segmentation
 7.4 Retail Pharmacies
  7.4.1 Introduction and Market Overview
  7.4.2 Key Market Trends, Growth Factors and Opportunities
  7.4.3 Impact of Covid-19
  7.4.4 Historic and Forecasted Market Size (2016-2028F)
  7.4.5 Key Market Trends, Growth Factors and Opportunities
  7.4.6 Retail Pharmacies: Geographic Segmentation
 7.5 Online Pharmacies
  7.5.1 Introduction and Market Overview
  7.5.2 Key Market Trends, Growth Factors and Opportunities
  7.5.3 Impact of Covid-19
  7.5.4 Historic and Forecasted Market Size (2016-2028F)
  7.5.5 Key Market Trends, Growth Factors and Opportunities
  7.5.6 Online Pharmacies: Geographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Zimbabwe Pharmaceutical Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Zimbabwe Pharmaceutical Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Zimbabwe Pharmaceutical Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 BAYER AG
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 CAPS PHARMACEUTICALS
 8.4 PFIZER INC
 8.5 PLUS FIVE PHARMACEUTICALS
 8.6 ZIMPHARM GRANITESIDE
 8.7 PHARMANOVA
 8.8 GULF DRUG
 8.9 DATLABS
 8.10 GLAXOSMITHKLINE PLC
 8.11 ICON PHARMACEUTICALS
 8.12 VARICHEM
 8.13 SEASONS PHARMACEUTICALS
 8.14 GRANITESIDE CHEMICALS (PVT) LTD
 8.15 OTHER MAJOR PLAYERS

Chapter 9 Investment Analysis

Chapter 10 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ZIMBABWE PHARMACEUTICAL MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ZIMBABWE PHARMACEUTICAL MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ZIMBABWE PHARMACEUTICAL MARKET COMPETITIVE RIVALRY
TABLE 005. ZIMBABWE PHARMACEUTICAL MARKET THREAT OF NEW ENTRANTS
TABLE 006. ZIMBABWE PHARMACEUTICAL MARKET THREAT OF SUBSTITUTES
TABLE 007. ZIMBABWE PHARMACEUTICAL MARKET BY DRUG TYPE
TABLE 008. PRESCRIPTION DRUGS MARKET OVERVIEW (2016-2028)
TABLE 009. OTC DRUGS MARKET OVERVIEW (2016-2028)
TABLE 010. ZIMBABWE PHARMACEUTICAL MARKET BY THERAPEUTIC CATEGORY
TABLE 011. CARDIOVASCULAR DISORDERS MARKET OVERVIEW (2016-2028)
TABLE 012. ANTI-VIRAL MARKET OVERVIEW (2016-2028)
TABLE 013. RESPIRATORY DISEASES MARKET OVERVIEW (2016-2028)
TABLE 014. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 015. ZIMBABWE PHARMACEUTICAL MARKET BY DISTRIBUTION CHANNEL
TABLE 016. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 017. RETAIL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 018. ONLINE PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 019. ZIMBABWE PHARMACEUTICAL MARKET, BY DRUG TYPE (2016-2028)
TABLE 020. ZIMBABWE PHARMACEUTICAL MARKET, BY THERAPEUTIC CATEGORY (2016-2028)
TABLE 021. ZIMBABWE PHARMACEUTICAL MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 022. ZIMBABWE PHARMACEUTICAL MARKET, BY COUNTRY (2016-2028)
TABLE 023. BAYER AG: SNAPSHOT
TABLE 024. BAYER AG: BUSINESS PERFORMANCE
TABLE 025. BAYER AG: PRODUCT PORTFOLIO
TABLE 026. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 026. CAPS PHARMACEUTICALS: SNAPSHOT
TABLE 027. CAPS PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 028. CAPS PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 029. CAPS PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 029. PFIZER INC: SNAPSHOT
TABLE 030. PFIZER INC: BUSINESS PERFORMANCE
TABLE 031. PFIZER INC: PRODUCT PORTFOLIO
TABLE 032. PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. PLUS FIVE PHARMACEUTICALS: SNAPSHOT
TABLE 033. PLUS FIVE PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 034. PLUS FIVE PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 035. PLUS FIVE PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. ZIMPHARM GRANITESIDE: SNAPSHOT
TABLE 036. ZIMPHARM GRANITESIDE: BUSINESS PERFORMANCE
TABLE 037. ZIMPHARM GRANITESIDE: PRODUCT PORTFOLIO
TABLE 038. ZIMPHARM GRANITESIDE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. PHARMANOVA: SNAPSHOT
TABLE 039. PHARMANOVA: BUSINESS PERFORMANCE
TABLE 040. PHARMANOVA: PRODUCT PORTFOLIO
TABLE 041. PHARMANOVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. GULF DRUG: SNAPSHOT
TABLE 042. GULF DRUG: BUSINESS PERFORMANCE
TABLE 043. GULF DRUG: PRODUCT PORTFOLIO
TABLE 044. GULF DRUG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. DATLABS: SNAPSHOT
TABLE 045. DATLABS: BUSINESS PERFORMANCE
TABLE 046. DATLABS: PRODUCT PORTFOLIO
TABLE 047. DATLABS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 048. GLAXOSMITHKLINE PLC: BUSINESS PERFORMANCE
TABLE 049. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 050. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. ICON PHARMACEUTICALS: SNAPSHOT
TABLE 051. ICON PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 052. ICON PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 053. ICON PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. VARICHEM: SNAPSHOT
TABLE 054. VARICHEM: BUSINESS PERFORMANCE
TABLE 055. VARICHEM: PRODUCT PORTFOLIO
TABLE 056. VARICHEM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. SEASONS PHARMACEUTICALS: SNAPSHOT
TABLE 057. SEASONS PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 058. SEASONS PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 059. SEASONS PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. GRANITESIDE CHEMICALS (PVT) LTD: SNAPSHOT
TABLE 060. GRANITESIDE CHEMICALS (PVT) LTD: BUSINESS PERFORMANCE
TABLE 061. GRANITESIDE CHEMICALS (PVT) LTD: PRODUCT PORTFOLIO
TABLE 062. GRANITESIDE CHEMICALS (PVT) LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 063. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 064. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 065. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ZIMBABWE PHARMACEUTICAL MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ZIMBABWE PHARMACEUTICAL MARKET OVERVIEW BY DRUG TYPE
FIGURE 012. PRESCRIPTION DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 013. OTC DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 014. ZIMBABWE PHARMACEUTICAL MARKET OVERVIEW BY THERAPEUTIC CATEGORY
FIGURE 015. CARDIOVASCULAR DISORDERS MARKET OVERVIEW (2016-2028)
FIGURE 016. ANTI-VIRAL MARKET OVERVIEW (2016-2028)
FIGURE 017. RESPIRATORY DISEASES MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 019. ZIMBABWE PHARMACEUTICAL MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 020. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 021. RETAIL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 022. ONLINE PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 023. ZIMBABWE PHARMACEUTICAL MARKET OVERVIEW BY COUNTRY (2016-2028)